论文部分内容阅读
目的探讨肝水解肽辅助治疗肝硬化失代偿期的临床疗效。方法选取2010年1月—2014年11月金溪县浒湾中心卫生院收治的102例肝硬化失代偿期患者,采用随机数字表法将患者分为研究组和对照组,各51例。对照组给予常规综合治疗,研究组在对照组基础上加用肝水解肽治疗,治疗3个月,比较两组患者临床疗效、治疗前后总胆红素(TBi L)、丙氨酸氨基转移酶(ALT)、清蛋白(ALB)水平及不良反应发生情况。结果研究组总有效率为92.2%,高于对照组的74.5%,差异有统计学意义(P<0.05)。治疗前,两组患者TBi L、ALT、ALB水平比较,差异无统计学意义(P>0.05);治疗后,研究组TBi L、ALT水平低于对照组,ALB水平高于对照组,差异有统计学意义(P<0.05)。两组患者治疗过程中均无不良反应发生。结论肝水解肽辅助治疗肝硬化失代偿期的临床疗效确切,可提高患者的免疫功能,促进正常肝细胞增殖、再生,促进病变组织恢复。
Objective To investigate the clinical efficacy of hepatic hydrolyzate in the treatment of decompensated liver cirrhosis. Methods From January 2010 to November 2014, 102 patients with decompensated liver cirrhosis admitted to Jinwan Hu Bay Central Hospital were enrolled. The patients were divided into study group and control group (n = 51) by random number table. The control group was given conventional comprehensive treatment. The study group was treated with hepatic hydrolytic peptide on the basis of the control group for 3 months. The clinical efficacy, total bilirubin (TBiL), alanine aminotransferase (ALT), albumin (ALB) levels and adverse reactions. Results The total effective rate of study group was 92.2%, which was higher than that of control group (74.5%), the difference was statistically significant (P <0.05). Before treatment, there was no significant difference in TBiL, ALT and ALB between the two groups (P> 0.05). After treatment, the levels of TBiL and ALT in the study group were lower than those in the control group, and the ALB levels were higher than those in the control group Statistical significance (P <0.05). No adverse reactions occurred in both groups during the course of treatment. Conclusion Hepatic hydrolytic peptide adjuvant treatment of decompensated cirrhosis of the clinical efficacy of definite, can improve the patient’s immune function, promote normal liver cell proliferation, regeneration, and promote the recovery of diseased tissue.